Corcept Therapeutics Incorporated (BIT:1CORT)

Market Cap	6.88B
Revenue (ttm)	634.17M
Net Income (ttm)	122.60M
Shares Out	n/a
EPS (ttm)	1.06
PE Ratio	56.12
Forward PE	43.49
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	n/a
Previous Close	63.00
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
RSI	n/a
Earnings Date	May 5, 2025

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical t...

• Industry: Pharmaceutical Preparations
• Founded: 1998
• Employees: 500
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1CORT

Financial Performance

In 2024, Corcept Therapeutics's revenue was $675.04 million, an increase of 39.94% compared to the previous year's $482.38 million. Earnings were $139.73 million, an increase of 32.45%.

Financial numbers in USD